Skip to main content

Insulin Glulisine Dosage

Medically reviewed by Drugs.com. Last updated on Mar 27, 2024.

Applies to the following strengths: 100 units/mL

Usual Adult Dose for Diabetes Type 1

Individualize dose based on metabolic needs and frequent monitoring of blood glucose


Multiple-daily injection (MDI):

Continuous Subcutaneous Infusion (Insulin Pump)

Intravenous Administration

Use: To improve glycemic control in adult patients with diabetes mellitus.

Usual Adult Dose for Diabetes Type 2

Individualize dose based on metabolic needs and frequent monitoring of blood glucose


Prandial Insulin:

Continuous Subcutaneous Infusion (Insulin Pump)

Intravenous Administration

Use: To improve glycemic control in patients with diabetes mellitus.

Usual Adult Dose for Diabetic Ketoacidosis

Successful treatment of hyperglycemic emergencies such as diabetic ketoacidosis (DKA) and hyperosmolar state (HHS) requires frequent monitoring of clinical and laboratory parameters while carefully correcting volume deficits, managing electrolytes, and normalizing blood glucose. Insulin therapy is used to slowly correct high glucose levels; consult current treatment protocols for specific guidance on fluid and electrolyte management.

Intravenous:


DKA: When blood glucose concentration reaches 200 mg/dL, decrease the insulin infusion to 0.02 to 0.05 unit/kg/hr; dextrose should be added to the IV fluids to maintain a blood glucose between 150 and 200 mg/dL until resolution of DKA (serum bicarbonate level 15 mEq/L or greater, venous pH greater than 7.3, and a calculated anion gap in the normal range)

HHS: When blood glucose concentration reaches 300 mg/dL or less, decrease the insulin infusion to 0.02 to 0.05 unit/kg/hr; dextrose should be added to the IV fluids to maintain blood glucose between 250 and 300 mg/dL until resolution of HHS.

Subcutaneous:

Comments:

Use: Treatment of hyperglycemic emergencies.

Usual Adult Dose for Nonketotic Hyperosmolar Syndrome

Successful treatment of hyperglycemic emergencies such as diabetic ketoacidosis (DKA) and hyperosmolar state (HHS) requires frequent monitoring of clinical and laboratory parameters while carefully correcting volume deficits, managing electrolytes, and normalizing blood glucose. Insulin therapy is used to slowly correct high glucose levels; consult current treatment protocols for specific guidance on fluid and electrolyte management.

Intravenous:


DKA: When blood glucose concentration reaches 200 mg/dL, decrease the insulin infusion to 0.02 to 0.05 unit/kg/hr; dextrose should be added to the IV fluids to maintain a blood glucose between 150 and 200 mg/dL until resolution of DKA (serum bicarbonate level 15 mEq/L or greater, venous pH greater than 7.3, and a calculated anion gap in the normal range)

HHS: When blood glucose concentration reaches 300 mg/dL or less, decrease the insulin infusion to 0.02 to 0.05 unit/kg/hr; dextrose should be added to the IV fluids to maintain blood glucose between 250 and 300 mg/dL until resolution of HHS.

Subcutaneous:

Comments:

Use: Treatment of hyperglycemic emergencies.

Usual Pediatric Dose for Diabetes Type 1

4 years and older: Individualize dose based on metabolic needs and frequent monitoring of blood glucose


Multiple-daily injection (MDI):

Continuous Subcutaneous Infusion (Insulin Pump)

Intravenous Administration

Use: To improve glycemic control in pediatric patients 4 years or older with type 1 diabetes mellitus.

Renal Dose Adjustments

Use with caution; frequent glucose monitoring and insulin dose reduction may be required

Liver Dose Adjustments

Use with caution; frequent glucose monitoring and insulin dose reduction may be required

Dose Adjustments


Supplemental doses may be prescribed during illness
Patients with type 2 diabetes receiving oral medications may be switched to insulin therapy temporarily.

Dosage adjustments may be required when the brand, type, or species of insulin is changed; oral antidiabetic treatment may need to be adjusted as well.

Precautions

Safety and efficacy in patients with type 1 diabetes mellitus have not been established in patients younger than 4 years.
Safety and efficacy in patients with type 2 diabetes mellitus have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Multiple-daily injections:

Continuous Subcutaneous Infusion (Insulin pump)

Intravenous:

Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.